Targeting mTOR-CCL20 Signaling May Improve Response to Docetaxel in Head and Neck Squamous Cell Carcinoma
Patients with advanced head and neck squamous cell carcinoma (HNSCC) usually show a dismal prognosis. It is this worthwhile to develop new, effective therapeutic regimens for these patients, such as molecular targeted therapy, which is promising as an alternative or combination treatment for HNSCC....
Main Authors: | Ming-Huei Chou, Hui-Ching Chuang, Yu-Tsai Lin, Ming-Hsien Tsai, Ying-Hsien Kao, I-Chun Lin, Tai-Lin Huang, Fu-Min Fang, Chih-Yen Chien |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/6/3046 |
Similar Items
-
Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells
by: Blaser Benjamin, et al.
Published: (2012-03-01) -
Comparison of anti-peritoneal fibrotic effects between an mTORC1-specific blocker and a PI3K/mTOR dual-blocker
by: Tian Xu, et al.
Published: (2019-01-01) -
Inhibition of esophageal cancer growth through the suppression of PI3K/AKT/mTOR signaling pathway
by: Shi N, et al.
Published: (2019-09-01) -
Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells
by: Hyera Kim, et al.
Published: (2020-04-01) -
Developing a novel dual PI3K–mTOR inhibitor from the prodrug of a metabolite
by: Zhou Y, et al.
Published: (2017-10-01)